Previous studies have found benefits of probiotics on increasing cognitive function in animals. With these promising results, this study is the first to look at the relation between probiotic supplementation and cognitive function in persons with Alzheimer’s disease. The study was randomized, double blind with 60 participants all diagnosed with Alzheimer’s disease. The participants were split into two groups, one the control who drank milk and the probiotic supplementation group. The probiotic supplementation group took 200mL of probiotic milk a day for 12 weeks.
The Government of Canada raises support in stem cell research. Stem cell research is classified as regenerative medicine. Using stem cells, you can regenerate and replace damaged cells, including tissues or organs that are affected by disease or illness. Stem cell research is currently being done for: spinal cord injuries, diabetes, arthritis, ALS, Parkinson’s disease, Alzheimer’s disease, macular degeneration, hair loss, and skin aging.
Eli Lilly’s experimental drug treatment results prove the drug to be ineffective. The drug, Solanezumab, was expected to slow the progression of Alzheimer’s diseases, and researchers had moderate expectations for the trial. However, the results proved the drug was not more effective than the placebo. The study was conducted with 2,100 people who are currently living with mild Alzheimer’s disease. Previous studies were conducted focused on persons with mild to moderate Alzheimer’s disease, but were not successful in slowing progression.
Across the globe dementia is an increasing health issue, with about a 5-7% risk of developing dementia for persons over 60 years of age. Many times dementia is proceeded with a diagnosis of mild cognitive impairment (MCI). Although MCI does not always develop into dementia, about 5-10% of those diagnosed with MCI receive a dementia diagnosis each year. This study looked at the benefits of using computerized cognitive training (CCT) as a safe and inexpensive intervention to maintain cognition.
A new study announced at the Society of Neuroscience 2016 Annual Conference looks into the “oldest of the old” who have above average cognitive functioning to understand why these individuals were protected from decline. Upon death, the brains of the individuals were looked at for characteristics of Alzheimer’s pathology; amyloid plaques and neurofibrillary tangles.